Dr. Ring is a recognized leader in the field of protein engineering and in its use for targeting novel pathways of the immune system. He was a primary inventor of the core technologies of Ab Initio Biotherapeutics.

He received his undergraduate training at Yale University and entered the Stanford Medical Scientist Training Program for his MD and PhD degrees. At Stanford, he worked in the laboratories of K. Christopher Garcia and Irving Weissman to use structure-based protein engineering to develop new cytokine and immune checkpoint therapies for cancer. He additionally developed novel methodologies in protein engineering to create biologic agents against challenging targets such as G protein coupled receptors (GPCRs).

Aaron joined the faculty of the Yale Department of Immunobiology in 2016 as the Robert T. McCluskey Yale Scholar. The focus of his research is to understand and manipulate the activity of immune receptors using structural and combinatorial biology approaches.

Yale, Stanford University, Healthcare, Business of Healthcare, Biologists, Forbes Top Lists, Co-founder, Entrepreneurship, Science, Scientists, Gene Therapy, Medicine, Biology, Immunology, Health, Epidemics & Pandemics